REG - Oxford Biomedica PLC - Block Listing Application

Oxford BioMedicaAnnouncement

23/01/2025 11:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250123:nRSW4802Ua&default-theme=true

RNS Number : 4802U  Oxford Biomedica PLC  23 January 2025

 

OXB

Block Listing Application

Oxford, UK - 23 January 2025: OXB (LSE: OXB), a quality and innovation-led
cell and gene therapy CDMO, today announces that application has been made to
the Financial Conduct Authority and the London Stock Exchange for admission
(i) to the Equity Shares (Commercial Companies) ("ESCC") category of the
Official List and (ii) to trading on the London Stock Exchange for a block
listing of 500,000 ordinary shares of 50 pence each in the capital of the
company (the "Ordinary Shares"), 300,000 of which will be issued from time to
time pursuant to the OXB Long Term Incentive Plan (LTIP), and 200,000 of which
will be issued from time to time pursuant to the OXB Deferred Bonus Plan
(DBP).

The Ordinary Shares are being reserved under a block listing and will be
issued from time to time pursuant to the following schemes:

 

·      OXB Long Term Incentive Plan (LTIP) (300,000 Ordinary Shares);
and

·      OXB Deferred Bonus Plan (DBP) (200,000 Ordinary Shares).

 

It is expected that admission to the Official List and the London Stock
Exchange of the New Ordinary Shares will become effective on 28 January 2025.
The New Ordinary Shares will rank pari passu in all respects with the
Company's existing ordinary shares in issue.

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

About OXB

 

OXB (LSE: OXB) is a quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25
years of experience in viral vectors; the driving force behind the majority of
cell and gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus and other viral vector types. OXB's world-class capabilities
span from early stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
Tetravecta™ system), dual plasmid system for AAV production, suspension and
perfusion process using process enhancers and stable producer and packaging
cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSFXLFLEFLBBBX